tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Fungemia D016469 2 associated lipids
Legionellosis D007876 3 associated lipids
Lung Abscess D008169 1 associated lipids
IgA Deficiency D017098 2 associated lipids
IgG Deficiency D017099 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
Alopecia Areata D000506 6 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Polymyositis D017285 1 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Blepharitis D001762 4 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Hypopigmentation D017496 2 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Erythema Nodosum D004893 5 associated lipids
Sweet Syndrome D016463 1 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Deglutition Disorders D003680 2 associated lipids
Oral Ulcer D019226 1 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Lupus Erythematosus, Cutaneous D008178 2 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Epididymitis D004823 1 associated lipids
Orchitis D009920 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Citrullinemia D020159 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Hand Injuries D006230 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Lichen Sclerosus et Atrophicus D018459 2 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Herpes Labialis D006560 1 associated lipids
Pemphigus D010392 3 associated lipids
Mutism D009155 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Rectal Fistula D012003 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Intestinal Atresia D007409 3 associated lipids
Priapism D011317 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Trichomonas Infections D014245 3 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
West Nile Fever D014901 1 associated lipids
Foot Ulcer D016523 4 associated lipids
Fibroadenoma D018226 2 associated lipids
Tinea Capitis D014006 1 associated lipids
Pancreatic Fistula D010185 2 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Lymphocele D008210 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Angiofibroma D018322 2 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Cheilitis D002613 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Optic Neuritis D009902 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Balanitis D001446 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Kuo CJ et al. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. 1992 Nature pmid:1614535
Japanese study of FK 506 on kidney transplantation: 2. Follow-up study of FK 506-treated patients. 1992 Transpl. Int. pmid:14621874
Chen TS et al. Microbial transformation of immunosuppressive compounds. I. Desmethylation of FK506 and immunomycin (FR 900520) by Actinoplanes sp. ATCC 53771. 1992 J. Antibiot. pmid:1372307
Walpoth B et al. Prevention of cardiac allograft rejection by FK506 and rapamycin: assessment by histology and nuclear magnetic resonance. 1992 Transpl. Int. pmid:14621877
Morisaki M and Arai T Identity of immunosuppressant FR-900520 with ascomycin. 1992 J. Antibiot. pmid:1372308
Doi R et al. Effects of FK506 on exocrine pancreas in rats. 1992 Pancreas pmid:1372739
Kawano K et al. FK 506 ameliorates normothermic liver ischemia in rats by suppressing production of tumor necrosis factor. 1992 Transpl. Int. pmid:14621904
Furukawa H et al. The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs. 1992 Transplantation pmid:1373531
Sakr M et al. Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation--incidence, location, and severity in cyclosporine- and FK506-treated patients. 1992 Transplantation pmid:1373535
Hirano Y et al. Morphological and functional changes of islets of Langerhans in FK506-treated rats. 1992 Transplantation pmid:1373536
Takahara S et al. The in vitro immunosuppressive effect of deoxymethylspergualin in man as compared with FK506 and cyclosporine. 1992 Transplantation pmid:1373537
Johnson MC et al. QT prolongation and Torsades de Pointes after administration of FK506. 1992 Transplantation pmid:1373538
Sigal NH and Dumont FJ Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. 1992 Annu. Rev. Immunol. pmid:1375473
Chen TS et al. Microbial transformation of immunosuppressive compounds. II. Specific desmethylation of 13-methoxy group of FK 506 and FR 900520 by an unidentified Actinomycete ATCC 53828 [corrected]. 1992 J. Antibiot. pmid:1375593
Meingassner JG and Stütz A Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? 1992 J. Invest. Dermatol. pmid:1375617
Schneck FX et al. Pediatric renal transplantation under FK-506 immunosuppression. 1992 J. Urol. pmid:1375663
Connelly PR and Thomson JA Heat capacity changes and hydrophobic interactions in the binding of FK506 and rapamycin to the FK506 binding protein. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1375751
Lancaster JR et al. EPR detection of heme and nonheme iron-containing protein nitrosylation by nitric oxide during rejection of rat heart allograft. 1992 J. Biol. Chem. pmid:1375934
Hirai T et al. The immunosuppressive effect of FK 506 on canine lung transplantation. 1992 J. Thorac. Cardiovasc. Surg. pmid:1375967
Tai PK et al. Association of a 59-kilodalton immunophilin with the glucocorticoid receptor complex. 1992 Science pmid:1376003
O'Keefe SJ et al. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. 1992 Nature pmid:1377361
Clipstone NA and Crabtree GR Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. 1992 Nature pmid:1377362
Hasegawa S et al. Combination use of suboptimal dose of FK 506 and cyclosporine in canine lung transplantation. 1992 J. Thorac. Cardiovasc. Surg. pmid:1279319
Peattie DA et al. Expression and characterization of human FKBP52, an immunophilin that associates with the 90-kDa heat shock protein and is a component of steroid receptor complexes. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1279700
Lhoëst G et al. Isolation and mass spectrometric identification of two metabolites of FK 506 from rat liver microsomal incubation media. 1992 Pharm Acta Helv pmid:1279730
Benigni A et al. The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. 1992 Transplantation pmid:1279848
Mor E et al. Late-onset acute rejection in orthotopic liver transplantation--associated risk factors and outcome. 1992 Transplantation pmid:1279849
Sawada M et al. Down regulation of CD4 expression in cultured microglia by immunosuppressants and lipopolysaccharide. 1992 Biochem. Biophys. Res. Commun. pmid:1282000
Minoda M et al. Effects of gamma-interferon and FK506 on resting B cell proliferation of New Zealand black/white F1 mice. 1992 Microbiol. Immunol. pmid:1282197
Min DI et al. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. 1992 Am J Hosp Pharm pmid:1282779
Mochizuki M [Immunotherapy in ocular diseases]. 1992 Nippon Ganka Gakkai Zasshi pmid:1283052
Olejniczak ET et al. A 4D HCCH-TOCSY experiment for assigning the side chain 1H and 13C resonances of proteins. 1992 J. Biomol. NMR pmid:1283353
Bauer S et al. The effect of the new immunosuppressive drug FK506 on the formation of secondary metabolites of cyclosporin A. 1992 Int J Clin Pharmacol Ther Toxicol pmid:1283385
Renoir JM et al. [Effect of immunosuppressants FK506 and rapamycin on the function of progesterone receptor: protein "p59-HBI", intersection between immunology and endocrinology?]. 1992 C. R. Acad. Sci. III, Sci. Vie pmid:1284044
Natazuka T FK506 reverses adriamycin resistance in a multidrug-resistant human leukemia cell line. 1992 Kobe J Med Sci pmid:1284834
Fukuse T et al. Optimal dose of FK 506 in canine lung allotransplantation. 1992 Transplant. Proc. pmid:1379757
Wada H et al. Combination use of suboptimal doses of FK 506 and cyclosporine in canine lung transplantation. 1992 Transplant. Proc. pmid:1379758
Cai X et al. Low-dose of FK 506 and associated blood levels in allotransplantation of rat liver, heart, and skin. 1992 Transplant. Proc. pmid:1379759
Taki J et al. DNA analysis of peripheral blood mononuclear cells for early detection of hepatic graft rejection. 1992 Transplant. Proc. pmid:1379760
Sato Y et al. FK 506 suppresses class II antigen expression in regenerating livers following partial hepatectomy in the rat. 1992 Transplant. Proc. pmid:1379761
Stütz A Immunosuppressive macrolides. 1992 Transplant. Proc. pmid:1379762
Leiva MC and Lyttle CR Leukocyte chemotactic activity of FKBP and inhibition by FK506. 1992 Biochem. Biophys. Res. Commun. pmid:1379802
Iwasaki K et al. Effect of repeated oral doses of a novel immunosuppressive macrolide lactone on hepatic mixed-function oxidase system in the rat. Comparative study with ciclosporin. 1992 Arzneimittelforschung pmid:1379812
Arceci RJ et al. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. 1992 Blood pmid:1381629
Pahl A and Keller U FK-506-binding proteins from streptomycetes producing immunosuppressive macrolactones of the FK-506 type. 1992 J. Bacteriol. pmid:1381710
Takahashi N [Cyclophilin and FK506-binding protein]. 1992 Seikagaku pmid:1381737
Lee TK et al. Mucosal glutamine utilization after small-bowel transplantation: an electrophysiologic study. 1992 J. Surg. Res. pmid:1382152
Kaye RE et al. Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1382293
Edalji R et al. High-level expression of recombinant human FK-binding protein from a fusion precursor. 1992 J. Protein Chem. pmid:1382438
Thomson AW and Starzl TE FK 506 and autoimmune disease: perspective and prospects. 1992 Autoimmunity pmid:1382646
Christians U et al. Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients. 1992 Clin. Chem. pmid:1382896
Chung J et al. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. 1992 Cell pmid:1377606
Xu RX et al. Stereospecific assignments and chi 1 rotamers for FKBP when bound to ascomycin from 3JH alpha,H beta and 3HN,H beta coupling constants. 1992 FEBS Lett. pmid:1377648
Petros AM et al. NMR studies of an FK-506 analog, [U-13C]ascomycin, bound to FK-506-binding protein. 1992 J. Med. Chem. pmid:1377749
Strom TB Molecular immunology and immunopharmacology of allograft rejection. 1992 Kidney Int. Suppl. pmid:1383599
Wang SC et al. FK-506 inhibits proliferation and IL-4 messenger RNA production by a T-helper 2 cell line. 1992 J. Surg. Res. pmid:1383612
Mizuno K et al. Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. 1992 Jan-Feb Anticancer Res. pmid:1373592
Arai S et al. The impact of FK506 on graft coronary disease of rat cardiac allograft--a comparison with cyclosporine. 1992 Jul-Aug J. Heart Lung Transplant. pmid:1379829
Fagiuoli S et al. FK 506: a new immunosuppressive agent for organ transplantation. Pharmacology, mechanism of action and clinical applications. 1992 Jul-Aug Ital J Gastroenterol pmid:1381245
Tong J et al. Effect of FK-506 and cyclosporin A on in vitro CFU-GM growth in severe aplastic anemia patients. 1992 Jul-Aug Haematologica pmid:1385279
Nazer H et al. FK 506 associated disorders in liver transplantation. 1992 May-Jun J. Gastroenterol. Hepatol. pmid:1377038
Bowman H and Lennard TW Immunosuppressive drugs. 1992 Nov 4-17 Br J Hosp Med pmid:1282440
Sattler M et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. 1992 Sep-Oct Drug Metab. Dispos. pmid:1385058
Nakajima K et al. Effects of triple therapy of cyclosporine, FK 506, and RS-61443 on allogeneic small bowel transplantation in dogs. 1993 Transplant. Proc. pmid:7679821
Tzakis AG et al. Two-year experience with FK 506 in pediatric patients. 1993 Transplant. Proc. pmid:7679822
Gibbs JF et al. Outcome analysis of FK 506 therapy for acute and chronic rejection. 1993 Transplant. Proc. pmid:7679823
Morphological characteristics of renal allografts showing renal dysfunction under FK 506 therapy: is graft biopsy available to reveal the morphological findings corresponding with FK 506 nephropathy? Japanese FK 506 Study Group. 1993 Transplant. Proc. pmid:7679824
Mañez R et al. Association between donor-recipient HLA-DR compatibility and cytomegalovirus hepatitis and chronic rejection in liver transplantation. 1993 Transplant. Proc. pmid:7680170
McCauley J The nephrotoxicity of FK506 as compared with cyclosporine. 1993 Curr. Opin. Nephrol. Hypertens. pmid:7532089
Woan MC et al. Characterization of the biopsy growth assay in monitoring cardiac transplant patients for rejection. 1993 Transplant. Proc. pmid:7680171
Rilo HR et al. Effect of intraportal human islet transplantation on kidney graft survival in simultaneous kidney-islet allografts. 1993 Transplant. Proc. pmid:7680172
Fukuzaki T et al. Induction of unresponsiveness to islet allograft by preoperative donor spleen cell injection and FK 506 treatment. 1993 Transplant. Proc. pmid:7680173
Deardon DJ et al. Small bowel tonometry: a possible technique for detecting early small bowel allograft dysfunction. 1993 Transplant. Proc. pmid:7505502
Demetris AJ et al. Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. 1993 Transplant. Proc. pmid:7505503
Pancer Z et al. cDNA cloning of a putative protochordate FK506-binding protein. 1993 Biochem. Biophys. Res. Commun. pmid:7505578
Woodle ES et al. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection. 1993 Transplant. Proc. pmid:7682358
Woodle ES et al. FK 506 rescue therapy: early conversion improves efficacy. 1993 Transplant. Proc. pmid:7682359
Woodle ES et al. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease. 1993 Transplant. Proc. pmid:7682360
Meiser BM et al. Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. 1993 Transplant. Proc. pmid:7682363
McCauley J et al. Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. 1993 Nephrol. Dial. Transplant. pmid:7508098
Schmitt J et al. Cloning and expression of a mouse cDNA encoding p59, an immunophilin that associates with the glucocorticoid receptor. 1993 Gene pmid:7693550
Nishikawa T et al. Kinetic analysis of molecular interconversion of immunosuppressant FK506 by high-performance liquid chromatography. 1993 Pharm. Res. pmid:7508108
Shafiee A et al. Enzymatic synthesis and immunosuppressive activity of novel desmethylated immunomycins (ascomycins). 1993 J. Antibiot. pmid:7693638
Keicho N et al. Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. 1993 J. Antibiot. pmid:7693639
Timerman AP et al. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. 1993 J. Biol. Chem. pmid:7693682
Takeda Y et al. Stimulation of endothelin mRNA and secretion in human endothelial cells by FK 506. 1993 J. Cardiovasc. Pharmacol. pmid:7509973
Wallemacq PE et al. Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 hours. 1993 Clin. Chem. pmid:7684956
Mochizuki M et al. A clinical trial of FK506 in refractory uveitis. 1993 Am. J. Ophthalmol. pmid:7685147
Renoir JM et al. Immunological identification of a 50 kDa Mr FK506-binding immunophilin as a component of the non-DNA binding, hsp90 and hsp70 containing, heterooligomeric form of the chick oviduct progesterone receptor. 1993 C. R. Acad. Sci. III, Sci. Vie pmid:7522118
Jung-Testas I et al. [Inhibition of the anti-glucocorticosteroid effect of RU486 on the growth of mouse fibroblasts in culture by the immunosuppressor kf506]]. 1993 C. R. Acad. Sci. III, Sci. Vie pmid:7522119
Nishizawa S et al. Therapeutic effect of a new immunosuppressant, FK-506, on vasospasm after subarachnoid hemorrhage. 1993 Neurosurgery pmid:7687044
Warty V et al. FK506 measurement: comparison of different analytical methods. 1993 Ther Drug Monit pmid:7687389
Iwata H et al. Suppression of allograft responses by combining donor alloantigen-specific intravenous presensitization with suboptimal doses of FK506. 1993 Transplantation pmid:7687396
Roelen DL et al. Differential inhibition of primed alloreactive CTLs in vitro by clinically used concentrations of cyclosporine and FK506. 1993 Transplantation pmid:7687397
Jost U et al. FK 506 treatment of intractable rejection after liver transplantation. 1993 Transplant. Proc. pmid:7689276
Winkler M et al. Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation. 1993 Transplant. Proc. pmid:7689277
Viebahn R et al. Simulation of hypoxic and preservation injury in human hepatocyte cultures: influence of FK 506 and cyclosporine. 1993 Transplant. Proc. pmid:7689278
Dé P et al. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3? 1993 Transplant. Proc. pmid:7689279
Lee KK et al. Successful treatment of ongoing intestinal allograft rejection permits recovery of graft structure and function. 1993 Am. J. Surg. pmid:7678188
Galvin F et al. Effects of cyclosporin A, FK 506, and mycalamide A on the activation of murine CD4+ T cells by the murine B7 antigen. 1993 Eur. J. Immunol. pmid:7678228